Study of KLS-1 for solid tumors and CLL
Part of Blood & lymphatic, Cancer, Digestive system, Hormones & metabolism, Immune system & allergy, Kidney & urinary, Skin clinical trials.
This trial tests a new drug called KLS-1 for people with solid tumors (like melanoma, pancreatic, or prostate cancer) or chronic lymphocytic leukemia (CLL) that is no longer responding to standard treatments. The goal is to see if KLS-1 is safe and can shrink tumors or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor (like melanoma, pancreatic, prostate, or others) or CLL that has gotten worse after at least one prior treatment.
- You are able to do daily activities with little to no help (performance status 0, 1, or 2).
- Your blood counts, liver, and kidney function are within certain limits (your doctor will check these).
- You have not had cancer therapy (chemotherapy, immunotherapy, etc.) for at least 30 days before starting the study, and any side effects from prior treatments have mostly resolved.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called QLS5212 in people with solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
This trial tests a new drug, QLS5132, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug called QLS5133 for people with advanced solid tumors that have not responded to other treatments. The drug is given alone, and the study aims to see if it is safe and effective.
This trial tests a new drug called ZL-6201 for people with sarcoma or certain solid tumors that have spread or cannot be removed. It aims to see if the drug is safe and helps shrink tumors.
This trial tests an experimental drug, QLS1209, for people with advanced solid tumors that have specific genetic changes (CCNE1 amplification, FBXW7 mutation, or PPP2R1A mutation). It aims to see if the drug is safe and effective for those who have not responded to standard treatments or have no standard options.
This study tests a new experimental drug called QLS5316 for people with advanced solid tumors that have not responded to standard treatments. The drug works like a 'smart bomb'—it seeks out and delivers medicine directly to cancer cells.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.